Daily supplements may cut heart risks for diabetes patients
NCT ID NCT06351566
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether taking daily vitamin D3 and prebiotics (inulin) for six months could improve heart health markers in 190 adults with type 2 diabetes. Researchers measured blood sugar control, cholesterol, and gut bacteria changes. The goal is to find simple dietary ways to lower cardiovascular risk in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vitamin D3 (cholecalciferol) and prebiotics (inulin)
What this could lead to
If it works, this could point toward a simple dietary supplement strategy to help manage heart disease risk in people with type 2 diabetes.
What could go wrong
This is a small, completed study, so results may not apply to everyone. Supplements are not a substitute for standard diabetes care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bao'an Center Hosipital of Shenzhen
Shenzhen, Guangdong, China
-
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China